Trial Profile

A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Combination With CAPOX and Sintilimab in Patients With Advanced, and Unresectable Gastric/Esophagogastric Junction Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ASKB 589 (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary) ; Sintilimab (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Adverse reactions
Sponsors AskGene Pharma

20 Jan 2024 Results (As of July 20, 2023, n=9 )presented at the 2024 Gastrointestinal Cancers Symposium
14 Feb 2023 Planned End Date changed from 12 Dec 2024 to 10 Feb 2026.
14 Feb 2023 Planned primary completion date changed from 12 Dec 2023 to 10 Feb 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com